Green Alexander L, Arnaud Axel, Batiller Jonathan, Eljamel Sam, Gauld Judi, Jones Peter, Martin Didier, Mehdorn Maximilian, Ohman Juha, Weyns Frank
a Department of Neurosurgery , John Radcliffe Hospital , Oxford , UK.
b ETHICON , Paris , France.
Br J Neurosurg. 2015 Feb;29(1):11-17. doi: 10.3109/02688697.2014.948808. Epub 2014 Aug 12.
Obtaining intra-operative watertight closure of the dura is considered important in reducing post-operative cerebrospinal fluid (CSF) leak. The purpose of this study was to evaluate a fibrin sealant as an adjunct to sutured dural repair to obtain intra-operative watertight closure in cranial neurosurgery.
This randomized, controlled multicenter study compared a fibrin sealant (EVICEL Fibrin Sealant [Human]) to sutured dural closure (Control). Subjects underwent supratentorial or posterior fossa procedures. Following primary dural repair by sutures, the closure was evaluated for intra-operative CSF leak by moderately increasing the intracranial pressure. If present, subjects were randomized to EVICEL or additional sutures (2:1 ratio), stratified by surgical approach. Following treatment, subjects were successful if no CSF leaks were present during provocative challenge. Safety was assessed to 30 days post-surgery, including incidence of CSF leakage.
One hundred and thirty-nine subjects were randomized: 89 to EVICEL and 50 to Control. Intra-operative watertight closure was achieved in 92.1% EVICEL-treated subjects versus 38.0% controls; a treatment difference of 54.1% (p < 0.001). The treatment differences in the supratentorial and posterior fossa strata were 49.1% and 75.7%, respectively (p < 0.001). The incidence of adverse events was similar between treatment groups. No deaths or unexpected serious adverse drug reactions were reported. CSF leakage within 30 days post-operatively was 2.2% and 2.0% in EVICEL and control groups, respectively. In addition, 2 cases of CSF rhinorrhoea were observed in the EVICEL group. Although not associated with the suture line where EVICEL was applied, when combined with the other CSF leaks, the observed leak rate in the EVICEL group was 4.5%.
These results indicate that EVICEL is effective as an adjunct to dural sutures to provide watertight closure of the dura mater in cranial surgery. The study confirmed the safety profile of EVICEL.
术中实现硬脑膜水密缝合被认为对减少术后脑脊液漏很重要。本研究的目的是评估一种纤维蛋白密封剂作为缝合硬脑膜修复的辅助手段,以在颅脑神经外科手术中实现术中硬脑膜水密缝合。
这项随机对照多中心研究将一种纤维蛋白密封剂(艾维可纤维蛋白密封剂[人源])与缝合硬脑膜闭合(对照组)进行了比较。受试者接受幕上或后颅窝手术。在通过缝合进行初次硬脑膜修复后,通过适度增加颅内压来评估闭合处是否存在术中脑脊液漏。如果存在脑脊液漏,受试者按手术入路分层,以2:1的比例随机分配至艾维可组或追加缝合组。治疗后,如果在激发试验期间没有脑脊液漏,则受试者视为成功。评估术后30天的安全性,包括脑脊液漏的发生率。
139名受试者被随机分组:89名接受艾维可治疗,50名作为对照组。接受艾维可治疗的受试者中有92.1%实现了术中硬脑膜水密缝合,而对照组为38.0%;治疗差异为54.1%(p<0.001)。幕上和后颅窝分层中的治疗差异分别为49.1%和75.7%(p<0.001)。治疗组之间不良事件的发生率相似。未报告死亡或意外的严重药物不良反应。艾维可组和对照组术后30天内脑脊液漏的发生率分别为2.2%和2.0%。此外,在艾维可组中观察到2例脑脊液鼻漏。虽然与应用艾维可的缝合线无关,但与其他脑脊液漏合并计算时,艾维可组观察到的漏率为4.5%。
这些结果表明,艾维可作为硬脑膜缝合的辅助手段,在颅脑手术中能有效地实现硬脑膜的水密缝合。该研究证实了艾维可的安全性。